Navigation Links
Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
Date:12/8/2007

PALO ALTO, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced positive results from the multicenter Phase 1 dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets in myelodysplastic syndrome (MDS) that support the initiation of Phase 2 clinical trials. The data were reported at the 49th annual meeting of the American Society of Hematology in Atlanta.

The objectives of the trial were to evaluate the safety and pharmacokinetics of TELINTRA Tablets (also known as TLK199 Tablets), and obtain preliminary indications of efficacy (International Working Group, IWG, 2000 criteria). The trial enrolled 45 patients and included all WHO classifications of MDS. Patients received one of ten dose levels of TELINTRA Tablets taken daily for seven days followed by two weeks of follow-up. Patients could receive planned therapy up to six months (eight cycles) until MDS progression or unacceptable toxicity.

TELINTRA Tablets were well-tolerated and no dose-limiting toxicities were observed. The most common non-hematologic toxicities were mild Grade 1 and 2 nausea, diarrhea and vomiting. Blood concentrations of the active metabolite of TELINTRA Tablets increased with dose levels.

Thirty-nine patients were evaluable for efficacy by objective Hematologic Improvement (HI) criteria. A dose-response curve was observed, with the majority of responses occurring in patients treated at the higher dose levels. Across all doses, neutrophil (HI-N) responses were observed in 21% (4 of 19) patients with neutrophil cytopenias. Seven of 21 patients (33%) with platelet cytopenias had HI-P. Among the 29 patients with erythroid cytopenias, HI-E was observed in six patients (21%). Some patients achieved red blood cell transfusion independence or a reduction in transfusion requirements, and one patient achieved platelet transfusion independence. One patient had a complete cytogenetic response.

"A tremendous need exists for new agents that are well-tolerated and efficacious for the treatment of MDS patients," said Azra Raza, M.D., Professor of Medicine and Director - MDS Program at St. Vincent's Comprehensive Cancer Center in New York City, and lead investigator on the TELINTRA Tablets study. "Having treated MDS patients with the intravenous formulation of TELINTRA, and now with the more convenient Tablet formulation, I am hopeful that planned Phase 2 dose-ranging trials will continue to demonstrate the potential for this agent to address early-stage MDS cytopenias as an alternative to blood support and best supportive care."

About TELINTRA

TELINTRA is an investigational small molecule designed to stimulate the production of blood cells in the bone marrow for the potential treatment of cytopenias associated with MDS or chemotherapy. Telik has developed both intravenous and Tablet formulations of TELINTRA, which was discovered through the application of Telik's proprietary TRAP(TM) drug discovery technology.

About Telik

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidates are TELCYTA(R), a tumor-activated small molecule product candidate in clinical development for the treatment of advanced ovarian cancer and non-small cell lung cancer; and TELINTRA(R), which is in development for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com

This press release contains "forward-looking" statements, including statements regarding Telik's future development plans for TELINTRA. These forward-looking statements are based upon Telik's current expectations. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product candidates or any product that Telik may develop, or obtain marketing approval before Telik does, Telik's commercial opportunity will be reduced or eliminated, and if Telik does not obtain regulatory approval to market products in the United States and foreign countries, Telik will not be permitted to commercialize its product candidates. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its quarterly report on Form 10-Q for the quarter ended September 30, 2007. Telik does not undertake any obligation to update forward-looking statements contained in this press release.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology: